Mette Schou Mikkelsen1, Jan Blaakaer2,3, Lone Kjeld Petersen4,3, Luise Gram Schleiss5, Lene Hjerrild Iversen6. 1. Department of Gynecology and Obstetrics, Aarhus University Hospital, Aarhus, Denmark. 2. Department of Clinical Research, University of Southern Denmark, Odense, Denmark. 3. Department of Gynecology and Obstetrics, Odense University Hospital, Odense, Denmark. 4. Open Patient Explorative Data Network, Department of Clinical Research, University of Southern Denmark, Odense, Denmark. 5. Discovery and Development PKPD, Novo Nordisk A/S, Maaloev, Denmark. 6. Department of Surgery, Aarhus University Hospital, Aarhus, Denmark.
Abstract
OBJECTIVES: Carboplatin is frequently used in various doses for hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of epithelial ovarian cancer (EOC) although its pharmacokinetics, including focus on the perfusion time, has not been evaluated when used in modern era cytoreductive surgery (CRS). The aim was to evaluate the pharmacokinetics and hematological toxicity of carboplatin used for HIPEC with a perfusion time of 90 min. METHODS: Fifteen patients with stage III-IV primary EOC received CRS and 90 min of HIPEC with carboplatin at dose 800 mg/m2. For the pharmacokinetic analysis, perfusate and blood samples were obtained during HIPEC and up to 48 h after HIPEC (blood only). Hematological toxicity within 30 days was graded according to Common Terminology Criteria for Adverse Events. Severe toxicity (grades 3-5) is reported. RESULTS: Mean maximum concentration of carboplatin was 12 times higher in perfusate than plasma (mean CmaxPF=348 µg/mL (range: 279-595 µg/mL) versus mean CmaxPL=29 µg/mL (range: 21-39 µg/mL)). Mean terminal half-life of carboplatin in perfusate was 104 min (range: 63-190 min) and mean intraperitoneal-to-plasma area under the concentration-time curve (AUC) ratio was 12.3 (range: 7.4-17.2). Two patients (13%) had grade 3 neutropenia within 30 days. No grade 4-5 hematological toxicities were identified. CONCLUSIONS: Carboplatin has a favorable pharmacokinetic profile for 90 min HIPEC administration, and the hematological toxicity was acceptable at dose 800 mg/m2. Large interindividual differences were found in the pharmacokinetic parameters, making risk of systemic exposure difficult to predict.
OBJECTIVES: Carboplatin is frequently used in various doses for hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of epithelial ovarian cancer (EOC) although its pharmacokinetics, including focus on the perfusion time, has not been evaluated when used in modern era cytoreductive surgery (CRS). The aim was to evaluate the pharmacokinetics and hematological toxicity of carboplatin used for HIPEC with a perfusion time of 90 min. METHODS: Fifteen patients with stage III-IV primary EOC received CRS and 90 min of HIPEC with carboplatin at dose 800 mg/m2. For the pharmacokinetic analysis, perfusate and blood samples were obtained during HIPEC and up to 48 h after HIPEC (blood only). Hematological toxicity within 30 days was graded according to Common Terminology Criteria for Adverse Events. Severe toxicity (grades 3-5) is reported. RESULTS: Mean maximum concentration of carboplatin was 12 times higher in perfusate than plasma (mean CmaxPF=348 µg/mL (range: 279-595 µg/mL) versus mean CmaxPL=29 µg/mL (range: 21-39 µg/mL)). Mean terminal half-life of carboplatin in perfusate was 104 min (range: 63-190 min) and mean intraperitoneal-to-plasma area under the concentration-time curve (AUC) ratio was 12.3 (range: 7.4-17.2). Two patients (13%) had grade 3 neutropenia within 30 days. No grade 4-5 hematological toxicities were identified. CONCLUSIONS: Carboplatin has a favorable pharmacokinetic profile for 90 min HIPEC administration, and the hematological toxicity was acceptable at dose 800 mg/m2. Large interindividual differences were found in the pharmacokinetic parameters, making risk of systemic exposure difficult to predict.
Authors: Danielle A Jandial; William E Brady; Stephen B Howell; Heather A Lankes; Russell J Schilder; Jan H Beumer; Susan M Christner; Sandra Strychor; Matthew A Powell; Andrea R Hagemann; Kathleen N Moore; Joan L Walker; Paul A DiSilvestro; Linda R Duska; Paula M Fracasso; Don S Dizon Journal: Gynecol Oncol Date: 2017-03-22 Impact factor: 5.482
Authors: H K Cho; R M Lush; D L Bartlett; H R Alexander; P C Wu; S K Libutti; K B Lee; D J Venzon; K S Bauer; E Reed; W D Figg Journal: J Clin Pharmacol Date: 1999-04 Impact factor: 3.126
Authors: Luigi Cattel; Michele De Simone; Roberto Passera; Maria Cristina Verlengo; Laura Delprino Journal: Anticancer Res Date: 2004 May-Jun Impact factor: 2.480
Authors: F Elferink; W J van der Vijgh; I Klein; W W ten Bokkel Huinink; R Dubbelman; J G McVie Journal: Cancer Chemother Pharmacol Date: 1988 Impact factor: 3.333
Authors: Vinicius de Lima Vazquez; O Anthony Stuart; Faheez Mohamed; Paul H Sugarbaker Journal: Cancer Chemother Pharmacol Date: 2003-05-21 Impact factor: 3.333
Authors: Oliver Zivanovic; Dennis S Chi; Olga Filippova; Leslie M Randall; Robert E Bristow; Roisin E O'Cearbhaill Journal: Gynecol Oncol Date: 2018-09-22 Impact factor: 5.482
Authors: Willemien J van Driel; Simone N Koole; Karolina Sikorska; Jules H Schagen van Leeuwen; Henk W R Schreuder; Ralph H M Hermans; Ignace H J T de Hingh; Jacobus van der Velden; Henriëtte J Arts; Leon F A G Massuger; Arend G J Aalbers; Victor J Verwaal; Jacobien M Kieffer; Koen K Van de Vijver; Harm van Tinteren; Neil K Aaronson; Gabe S Sonke Journal: N Engl J Med Date: 2018-01-18 Impact factor: 91.245
Authors: E F McClay; R Goel; P Andrews; S Gorelick; S Kirmani; S Kim; P Braly; S Plaxe; S Hoff; J Alcaraz Journal: Br J Cancer Date: 1993-10 Impact factor: 7.640
Authors: Elisabeth K Petersen; Mats Bue; Christina Harlev; Andrea R Jørgensen; Anne Schmedes; Pelle Hanberg; Lone K Petersen; Maiken Stilling Journal: Pleura Peritoneum Date: 2022-06-06